Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer

K. Ribi, J. Aldridge, K. A. Phillips, A. Thompson, V. Harvey, B. Thürlimann, F. Cardoso, O. Pagani, A. S. Coates, A. Goldhirsch, K. N. Price, R. D. Gelber, J. Bernhard

Research output: Contribution to journalArticle

Abstract

Background: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF). Methods: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored. Results: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P=0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R0.80). Correlations between SCF and the other patient-reported outcomes were generally low. Conclusion: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute.

Original languageEnglish
Pages (from-to)1618-1625
Number of pages8
JournalBritish Journal of Cancer
Volume106
Issue number10
DOIs
Publication statusPublished - May 8 2012

    Fingerprint

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • Letrozole
  • Quality of life
  • Subjective cognitive function
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ribi, K., Aldridge, J., Phillips, K. A., Thompson, A., Harvey, V., Thürlimann, B., Cardoso, F., Pagani, O., Coates, A. S., Goldhirsch, A., Price, K. N., Gelber, R. D., & Bernhard, J. (2012). Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. British Journal of Cancer, 106(10), 1618-1625. https://doi.org/10.1038/bjc.2012.156